Physician profile
Matthew Wayne Jackson
NPI 1821359795
$2,069.93
in general payments reported to CMS, 2019-2025
27 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $535 · 2021: $524 · 2022: $347 · 2023: $125 · 2024: $24.19 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $303.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $277.14 | 2019-2024 | Opdivo |
| Amgen INC. | $178.53 | 2019-2023 | Kyprolis, Blincyto |
| Teleflex LLC | $141.88 | 2025 | Barrigel |
| Seagen INC. | $125.05 | 2020-2023 | Padcev |
| Merck Sharp & Dohme LLC | $116.63 | 2019-2023 | Keytruda |
| Incyte Corporation | $109.92 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.63 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $76.75 | 2019-2020 | |
| Eisai INC. | $72.79 | 2020-2023 | |
| Puma Biotechnology, INC. | $71.70 | 2020-2021 | |
| Taiho Oncology, INC. | $71.62 | 2020-2022 | |
| Rigel Pharmaceuticals, INC. | $64.65 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $57.10 | 2020-2021 | |
| Janssen Biotech, INC. | $50.62 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $45.71 | 2019-2022 | |
| Mirati Therapeutics, INC. | $21.58 | 2023 | Krazati |
| Adaptive Biotechnologies Corporation | $19.63 | 2022 | |
| Exelixis INC. | $17.37 | 2022 | |
| Boston Scientific Corporation | $17.04 | 2019 | |
| Celgene Corporation | $14.84 | 2019 | |
| Karyopharm Therapeutics INC. | $13.79 | 2021 | |
| Morphosys, US INC. | $13.48 | 2022 | |
| Daiichi Sankyo INC. | $12.77 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.36 | 2021 | |
| Foundation Medicine, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.